Petosemtamab demonstrates encouraging objective response rates (ORRs), with promising depth and durability of response, in first- and second-line metastatic colorectal cancer (mCRC) Data reinforces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results